Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | FLT3 | P36888 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | BLK | P51451 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022542 | 0.87 | CYP1A2 (0.36) | KCNH2CYP1A2CLK4USP2FLT3 | |
| SCHEMBL3016541 | 0.83 | KCNH2 (0.50) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3027130 | 0.83 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL3666200 | 0.81 | KCNH2 (0.34) | KCNH2CYP1A2CLK4USP2FLT3 | |
| SCHEMBL3020131 | 0.79 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL3027712 | 0.79 | CRBN (0.34) | KCNH2 | |
| SCHEMBL3666949 | 0.79 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL3719019 | 0.79 | KCNH2 (0.37) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3027143 | 0.79 | CRBN (0.33) | KCNH2 | |
| SCHEMBL3670290 | 0.79 | KCNH2 (0.31) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| EP-2139898-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | KCNH2 2445/4885CYP1A2 1494/4885CLK4 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.